402 related articles for article (PubMed ID: 26541342)
1. Does emerging Clarithromycin resistance signal an obituary to empirical standard triple therapy for Helicobacter pylori infection?
John A; Al Kaabi S; Doiphode S; Chandra P; Sharma M; Babu R; Yacoub R; Derbala M
Indian J Gastroenterol; 2015 Sep; 34(5):404-7. PubMed ID: 26541342
[TBL] [Abstract][Full Text] [Related]
2. [Acquisition of secondary resistance after failure of a first treatment of Helicobacter pylori infection in children].
Kalach N; Benhamou PH; Bergeret M; Gottrand F; Husson MO; Barbier C; Dupont C; Raymond J
Arch Pediatr; 2002 Feb; 9(2):130-5. PubMed ID: 11915493
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication.
Choi IJ; Jung HC; Choi KW; Kim JH; Ahn DS; Yang US; Rew JS; Lee SI; Rhee JC; Chung IS; Chung JM; Hong WS
Aliment Pharmacol Ther; 2002 Jan; 16(1):145-51. PubMed ID: 11856089
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of antimicrobial resistance of Helicobacter pylori isolates in the Smolensk region of Russian Federation.
Dekhnich N; Ivanchik N; Kozlov R; Alimov A; Steshits A; Kirsov P; Pandav K
Helicobacter; 2018 Dec; 23(6):e12545. PubMed ID: 30324756
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibility testing before first-line treatment for
Cosme A; Montes M; Ibarra B; Tamayo E; Alonso H; Mendarte U; Lizasoan J; Herreros-Villanueva M; Bujanda L
World J Gastroenterol; 2017 May; 23(18):3367-3373. PubMed ID: 28566898
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic susceptibility of Helicobacter pylori in Iceland.
Gunnarsdottir AI; Gudjonsson H; Hardardottir H; Jonsdottir KD; Bjornsson ES
Infect Dis (Lond); 2017 Sep; 49(9):647-654. PubMed ID: 28440099
[TBL] [Abstract][Full Text] [Related]
7. ANTIBIOTIC RESISTANCE SURVEILLANCE OF HELICOBACTER PYLORI AT THE BIOBÍO REGION (CHILE) IN A DECADE.
Parra-Sepúlveda C; Merino JS; Sáez-Carrillo K; González C; García-Cancino A
Arq Gastroenterol; 2019; 56(4):361-366. PubMed ID: 31721972
[TBL] [Abstract][Full Text] [Related]
8. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.
Almeida N; Romãozinho JM; Donato MM; Luxo C; Cardoso O; Cipriano MA; Marinho C; Sofia C
Helicobacter; 2014 Apr; 19(2):90-7. PubMed ID: 24506175
[TBL] [Abstract][Full Text] [Related]
9. In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy.
Di Giulio M; Di Campli E; Di Bartolomeo S; Cataldi V; Marzio L; Grossi L; Ciccaglione AF; Nostro A; Cellini L
Scand J Gastroenterol; 2016 Mar; 51(3):263-9. PubMed ID: 26554617
[TBL] [Abstract][Full Text] [Related]
10. Ten-day triple therapy versus sequential therapy versus concomitant therapy as first-line treatment for Helicobacter pylori infection.
Ang TL; Fock KM; Song M; Ang D; Kwek AB; Ong J; Tan J; Teo EK; Dhamodaran S
J Gastroenterol Hepatol; 2015 Jul; 30(7):1134-9. PubMed ID: 25639278
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
Magaret N; Burm M; Faigel D; Kelly C; Peterson W; Fennerty MB
Dig Dis; 2001; 19(2):174-8. PubMed ID: 11549829
[TBL] [Abstract][Full Text] [Related]
12. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal.
Miftahussurur M; Shrestha PK; Subsomwong P; Sharma RP; Yamaoka Y
BMC Microbiol; 2016 Nov; 16(1):256. PubMed ID: 27809767
[TBL] [Abstract][Full Text] [Related]
13. Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial.
Sarkeshikian SS; Iranikhah A; Ghadir MR
Turk J Gastroenterol; 2013; 24(1):10-4. PubMed ID: 23794338
[TBL] [Abstract][Full Text] [Related]
14. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
[TBL] [Abstract][Full Text] [Related]
15. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study.
Peitz U; Sulliga M; Wolle K; Leodolter A; Von Arnim U; Kahl S; Stolte M; Börsch G; Labenz J; Malfertheiner P
Aliment Pharmacol Ther; 2002 Feb; 16(2):315-24. PubMed ID: 11860415
[TBL] [Abstract][Full Text] [Related]
16. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole.
Marzio L; Coraggio D; Capodicasa S; Grossi L; Cappello G
Helicobacter; 2006 Aug; 11(4):237-42. PubMed ID: 16882326
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication.
Ellenrieder V; Boeck W; Richter C; Marre R; Adler G; Glasbrenner B
Scand J Gastroenterol; 1999 Aug; 34(8):750-6. PubMed ID: 10499474
[TBL] [Abstract][Full Text] [Related]
18. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey.
Caliskan R; Tokman HB; Erzin Y; Saribas S; Yuksel P; Bolek BK; Sevuk EO; Demirci M; Yılmazli O; Akgul O; Kalayci F; Cakan H; Salih B; Bal K; Kocazeybek B
Rev Soc Bras Med Trop; 2015; 48(3):278-84. PubMed ID: 26108005
[TBL] [Abstract][Full Text] [Related]
20. Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: A prospective multicenter study.
Lee JH; Ahn JY; Choi KD; Jung HY; Kim JM; Baik GH; Kim BW; Park JC; Jung HK; Cho SJ; Shin CM; Choi YJ; Lee SH; Kim JH; Lee WS; Sung JK; Chung JW; Cheung DY; Lee H; Min YW; Kim JJ; Kim SY; ;
Helicobacter; 2019 Aug; 24(4):e12592. PubMed ID: 31111572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
